Please assess the completion status of the following clinical trial:

Trial Title: Alemtuzumab to Treat Severe Aplastic Anemia

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
* INCLUSION CRITERIA:~Relapsed severe aplastic anemia after initial hematologic response to a prior course of h-ATG or r-ATG based immunosuppression~Or~Refractory severe aplastic anemia not responding to both horse-ATG and rabbit ATG-based immunosuppression~The criteria for severe aplastic anemia are two of the three criteria:~* Absolute neutrophil count less than or equal to 500 /mm(3)~* Platelets to less than or equal to 20,000/mm(3)~* Absolute reticulocyte count less than 60,000 /microL~Age greater than or equal to 2 years old and greater than 12 kg~Prospective subjects or their parent(s)/responsible guardian(s) must be able to comprehend and be willing to sign an informed consent.~EXCLUSION CRITERIA:~Known Diagnosis of Fanconi's anemia~Evidence of a clonal disorder on cytogenetics. In the refractory disease setting, prospective subjects with super severe neutropenia (ANC less than 200 /microL) will not be excluded if results of cytogenetics are not available or pending.~Infection not adequately responding to appropriate therapy~HIV positivity~Failure to discontinue the herbal supplements Echinacea purpurea or Usnea barbata (Old Man's Beard) within 2 weeks of enrollment~Moribund status or concurrent hepatic, renal, cardiac, neurologic, pulmonary, infectious, or metabolic disease of such severity that it would preclude the patient's ability to tolerate protocol therapy, or that death within 7-10 days is likely~Previous hypersensitivity to alemtuzumab or its components~Potential subjects with cancer who are on active chemotherapeutic treatment or who take drugs with hematological effects will not be eligible~Current pregnancy, or unwilling to take oral contraceptives or refrain from pregnancy if of childbearing potential~Not able to understand the investigational nature of the study or give informed consent

- Gender: ALL
- Minimum Age: 2 Years
- Maximum Age: 110 Years
- Healthy Volunteers: f

Study Arms:
- Relapsed severe aplastic anemia (Type: EXPERIMENTAL): Subjects diagnosed with relapsed severe aplastic anemia
- Refractory severe asplastic anemia (Type: EXPERIMENTAL): Subjects diagnosed with refractory severe aplastic anemia
- Relapse after Alemtuzumab (Type: EXPERIMENTAL): Subjects who relapse after initial response to alemtuzumab therapy will have cyclosporine added to the regimen after the 6 month visit.

Based on this trial design, predict the completion outcome and termination type (if applicable).